MedPageToday -- Prophylactic treatment with intravenous immunoglobulin (IVIg) failed to show benefits in neonatal rhesus hemolytic disease, according to results from a randomized controlled trial. There was no difference in the rate of exchange transfusions among infants who received IVIg and controls (17% versus 15%, P=0.99), reported Vivianne E.H.J. Smits-Wintjens, MD, of Leiden University in the Netherlands, and colleagues.